Financial Performance Forecast - The estimated net profit for 2024 is projected to be between 8 million and 12 million yuan, representing a decline of 70.24% to 80.16% compared to the previous year's profit of 40.3188 million yuan[3]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of 13.24 million yuan, a decrease of 207.69% to 240.23% from a profit of 12.2941 million yuan in the same period last year[3]. - The performance forecast period is from January 1, 2024, to December 31, 2024[3]. - The specific financial data for the 2024 annual performance will be disclosed in the company's annual report after the audit[7]. Factors Affecting Performance - The decline in performance is primarily attributed to intensified competition in the domestic life sciences service market and increased operating costs from the new production line for self-owned brand products[5]. - The company has increased its investment in R&D for self-owned products as part of its antibody strategy, impacting overall profitability[5]. - The earnings forecast indicates a significant operational challenge for the company in the upcoming fiscal year[5]. Non-Recurring Gains and Losses - Non-recurring gains and losses for the reporting period are estimated at 25.24 million yuan, mainly from bank cash management income and government subsidies[6]. - The financial data in the earnings forecast is preliminary and has not been audited by the accounting firm[4]. Investor Guidance - The company emphasizes the importance of cautious decision-making and awareness of investment risks for investors[7].
优宁维(301166) - 2024 Q4 - 年度业绩预告